/Companies

Asgard Therapeutics

Lund, SE · Founded 2018 · 29 employees on LinkedIn · 5 known investors

Find your way into Asgard Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

222 people can intro you to Filipe

Ask Adam Stokes to introduce you to Filipe Pereira

You →Adam · together at Mary Ann Liebert, Inc. →Filipe

167 people can intro you to Fábio

Ask Jamie Chen to introduce you to Fábio Rosa

You →Jamie · together at Asgard Therapeutics →Fábio

Sign up to find every way you can get introduced to Asgard Therapeutics

  • Your email: who you already know at Asgard Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Asgard Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.

Founders & leadership

Asgard Therapeutics was founded in 2018 by Cristiana Pires, Fábio Rosa, and Filipe Pereira.

CPCristiana Pires
Cristiana PiresCo-founder and CEO
FRFábio Rosa
Fábio RosaCo-founder and VP of ResearchFábio Rosa studied transcription factors and cellular reprogramming during his research career, focusing on methods to induce dendritic cell fate. He is co-founder and VP of Research at Asgard Therapeutics, a cancer immunotherapy company developing direct cell reprogramming technologies.
FPFilipe Pereira
Filipe PereiraCo-founder and Head of InnovationFilipe Pereira is a Professor of Molecular Medicine at Lund University with 20 years of research experience in cellular reprogramming and immunology. He earned his Ph.D. from Imperial College London and conducted postdoctoral research at Mount Sinai, where he developed approaches to apply cellular reprogramming to hematopoiesis; he co-founded Asgard Therapeutics to translate dendritic cell reprogramming into cancer immunotherapy.

Investors · 5

Funding

SEC filings, press & company announcements

$30M disclosed across 1 of 2 rounds · 2021–2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Frequently asked questions

What does Asgard Therapeutics do?
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses. The company focuses on oncology immunotherapy through its TrojanDC approach.
Who founded Asgard Therapeutics?
Asgard Therapeutics was founded by Cristiana Pires, Fábio Rosa, Filipe Pereira in 2018.
Who are Asgard Therapeutics's investors?
Asgard Therapeutics's investors include Industrifonden, LU Innovation, Novo Holdings, RV Invest GmbH, Boehringer Ingelheim Venture Fund.
How much funding has Asgard Therapeutics raised?
Asgard Therapeutics has disclosed $30M raised across 1 of its 2 known rounds.
Where is Asgard Therapeutics headquartered?
Asgard Therapeutics is headquartered in Lund, SE.